BR112023025738A2 - Combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, uso de uma combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, método para o tratamento ou profilaxia de câncer, composição farmacêutica e invenção - Google Patents
Combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, uso de uma combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, método para o tratamento ou profilaxia de câncer, composição farmacêutica e invençãoInfo
- Publication number
- BR112023025738A2 BR112023025738A2 BR112023025738A BR112023025738A BR112023025738A2 BR 112023025738 A2 BR112023025738 A2 BR 112023025738A2 BR 112023025738 A BR112023025738 A BR 112023025738A BR 112023025738 A BR112023025738 A BR 112023025738A BR 112023025738 A2 BR112023025738 A2 BR 112023025738A2
- Authority
- BR
- Brazil
- Prior art keywords
- combination
- binding antagonist
- braf inhibitor
- axis binding
- cancer
- Prior art date
Links
- 229940125431 BRAF inhibitor Drugs 0.000 title abstract 5
- 239000005557 antagonist Substances 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000011321 prophylaxis Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, uso de uma combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, método para o tratamento ou profilaxia de câncer, composição farmacêutica e invenção. a presente invenção é direcionada a uma combinação do inibidor de braf n-[2-ciano-4-fluoro-3-(3-metil-4-oxo-quinazolin-6-il)oxi-fenil]-3-fluoro-pirrolidina-1-sulfonamida ou um sal ou solvato farmaceuticamente aceitável do mesmo com um antagonista de ligação ao eixo pd-1, e ao uso da combinação como medicamento, em particular, para o tratamento terapêutico e/ou profilático de câncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21178462 | 2021-06-09 | ||
EP22157499 | 2022-02-18 | ||
PCT/EP2022/065373 WO2022258600A1 (en) | 2021-06-09 | 2022-06-07 | Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023025738A2 true BR112023025738A2 (pt) | 2024-02-27 |
Family
ID=82196559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023025738A BR112023025738A2 (pt) | 2021-06-09 | 2022-06-07 | Combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, uso de uma combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, método para o tratamento ou profilaxia de câncer, composição farmacêutica e invenção |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP4351582A1 (pt) |
KR (1) | KR20240019109A (pt) |
AU (1) | AU2022289684A1 (pt) |
BR (1) | BR112023025738A2 (pt) |
CA (1) | CA3216220A1 (pt) |
IL (1) | IL308015A (pt) |
TW (1) | TW202313045A (pt) |
WO (1) | WO2022258600A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2022383040A1 (en) * | 2021-11-04 | 2024-03-07 | F. Hoffmann-La Roche Ag | Novel use of quinazolinone compound for the treatment of cancer |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1984003506A1 (en) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Antigenically active amino acid sequences |
JPS60500673A (ja) | 1983-03-08 | 1985-05-09 | コモンウエルス セラム ラボラトリ−ズ コミツシヨン | 抗原活性を有するアミノ酸配列 |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5571689A (en) | 1988-06-16 | 1996-11-05 | Washington University | Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5663143A (en) | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
AU668347B2 (en) | 1990-11-21 | 1996-05-02 | Torrey Pines Institute For Molecular Studies | Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
WO1998058964A1 (en) | 1997-06-24 | 1998-12-30 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
EP2261229A3 (en) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
ES2420835T3 (es) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de las moléculas inmunofuncionales |
WO2001007611A2 (en) | 1999-07-26 | 2001-02-01 | Genentech, Inc. | Novel polynucleotides and method for the use thereof |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
MXPA02003456A (es) | 1999-10-04 | 2002-10-23 | Medicago Inc | Metodo para regular la transcripcion de genes foraneos. |
JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
WO2001044463A1 (en) | 1999-12-15 | 2001-06-21 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
CN101940189A (zh) | 2000-11-30 | 2011-01-12 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES |
ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
WO2003085119A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia |
CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
AU2003236019A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism |
CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
AU2003239966B9 (en) | 2002-06-03 | 2010-08-26 | Genentech, Inc. | Synthetic antibody phage libraries |
PL212899B1 (pl) | 2002-12-16 | 2012-12-31 | Genentech Inc | Humanizowane przeciwcialo, kompozycja zawierajaca to przeciwcialo, wyrób fabryczny, przeciwcialo lub jego fragment do zastosowania w sposobie indukowania apoptozy, izolowany kwas nukleinowy, wektor ekspresji, komórka gospodarza, sposób wytwarzania przeciwciala lub jego fragmentu, plynny preparat i zastosowanie przeciwciala do wytwarzania leku |
EP1585767A2 (en) | 2003-01-16 | 2005-10-19 | Genentech, Inc. | Synthetic antibody phage libraries |
NZ603037A (en) | 2003-01-22 | 2014-05-30 | Roche Glycart Ag | Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
CA2542046A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
CA2542125A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase |
HUE031632T2 (en) | 2003-11-05 | 2017-07-28 | Roche Glycart Ag | Antigen binding molecules with enhanced Fc receptor binding affinity and effector function |
JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
JP5128935B2 (ja) | 2004-03-31 | 2013-01-23 | ジェネンテック, インコーポレイテッド | ヒト化抗TGF−β抗体 |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
TW200812616A (en) | 2006-05-09 | 2008-03-16 | Genentech Inc | Binding polypeptides with optimized scaffolds |
PL2059533T3 (pl) | 2006-08-30 | 2013-04-30 | Genentech Inc | Przeciwciała wieloswoiste |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
US8592562B2 (en) | 2008-01-07 | 2013-11-26 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
WO2012118492A1 (en) | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
CN105899493B (zh) | 2014-01-17 | 2019-03-29 | 诺华股份有限公司 | 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物 |
ES2699351T3 (es) | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
WO2018075447A1 (en) * | 2016-10-19 | 2018-04-26 | The Trustees Of Columbia University In The City Of New York | Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma) |
KR20200070295A (ko) | 2017-10-12 | 2020-06-17 | 레볼루션 메디슨즈, 인크. | 알로스테릭 shp2 억제제로서의 피리딘, 피라진 및 트리아진 화합물 |
PE20221778A1 (es) * | 2019-12-10 | 2022-11-16 | Hoffmann La Roche | Nuevos derivados de metilquinazolinona |
-
2022
- 2022-06-07 BR BR112023025738A patent/BR112023025738A2/pt unknown
- 2022-06-07 IL IL308015A patent/IL308015A/en unknown
- 2022-06-07 EP EP22733341.6A patent/EP4351582A1/en active Pending
- 2022-06-07 AU AU2022289684A patent/AU2022289684A1/en active Pending
- 2022-06-07 TW TW111121104A patent/TW202313045A/zh unknown
- 2022-06-07 KR KR1020237041756A patent/KR20240019109A/ko unknown
- 2022-06-07 WO PCT/EP2022/065373 patent/WO2022258600A1/en active Application Filing
- 2022-06-07 CA CA3216220A patent/CA3216220A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TW202313045A (zh) | 2023-04-01 |
CA3216220A1 (en) | 2022-12-15 |
WO2022258600A1 (en) | 2022-12-15 |
EP4351582A1 (en) | 2024-04-17 |
KR20240019109A (ko) | 2024-02-14 |
AU2022289684A1 (en) | 2023-10-05 |
IL308015A (en) | 2023-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022009571A2 (pt) | Uso de inibidor de fak na preparação de um fármaco para tratar tumores que têm mutação nras | |
BR112018001640A2 (pt) | combinação de antagonista da pd-1 com um inibidor de egfr | |
MX2021004110A (es) | Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina. | |
BR112020019875A8 (pt) | composições tópicas para alívio da dor | |
BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
MX2021001807A (es) | Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma. | |
BR112023015067A2 (pt) | Composto de quinazolina para induzir a degradação de proteína kras g12d mutante | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
MX2021015770A (es) | Inhibidores macrociclicos de mcl-1. | |
MX2022000390A (es) | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. | |
BR112023025738A2 (pt) | Combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, uso de uma combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, método para o tratamento ou profilaxia de câncer, composição farmacêutica e invenção | |
BR112019002945A2 (pt) | terapia de combinação para o tratamento de câncer pancreático | |
WO2015035410A8 (en) | Cancer therapy | |
BR112016030275A2 (pt) | Métodos para tratamento e redução dos sintomas da síndrome mão-pé (eritrodisestesia palmo-plantar) | |
BR112019007863A2 (pt) | derivados de naftiridinona inovadores e seu uso no tratamento de arritmia | |
BR112018072298A2 (pt) | tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase | |
BRPI1008000A2 (pt) | composto, hidrobrometo, hidrocloreto, metanossulfonato, etano-1, 2-dissulfonato, inibidor de hsp90, agente para inibir a atividade de atpase de hsp90, agente para inibir a ligação de hsp90 em atp, medicamento, agente anticâncer, composição farmacêutica, método para tratar câncer, e, uso de um composto. | |
BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
BR112022008610A2 (pt) | Composições tópicas compreendendo inibidores de irak4 para uso em tratamento de condições dermatológicas caracterizadas por inflamação | |
BR112019008698A2 (pt) | método para tratar câncer num sujeito que precisa do mesmo e composição farmacêutica | |
BR112014030288A8 (pt) | composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila | |
CR20210514A (es) | USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183) | |
BR112018073396A2 (pt) | combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
BR112022009754A2 (pt) | Derivados macrocíclicos de sulfonila como inibidores de mcl-1 |